Sex as a Biological Variable in Emergency Medicine Research and Clinical Practice: A Brief Narrative Review

Alyson J. McGregor, MD, MA
Gillian A. Beauchamp, MD†
Charles R. Wira III, MD‡
Sarah M. Perman, MD, MSCE§
Basmah Safdar, MD‡

The National Institutes of Health recently highlighted the significant role of sex as a biological variable (SABV) in research design, outcome and reproducibility, mandating that this variable be accounted for in all its funded research studies. This move has resulted in a rapidly increasing body of literature on SABV with important implications for changing the clinical practice of emergency medicine (EM). Translation of this new knowledge to the bedside requires an understanding of how sex-based research will ultimately impact patient care. We use three case-based scenarios in acute myocardial infarction, acute ischemic stroke and important considerations in pharmacologic therapy administration to highlight available data on SABV in evidence-based research to provide the EM community with an important foundation for future integration of patient sex in the delivery of emergency care as gaps in research are filled. [West J Emerg Med. 2017;18(6)1079-1090.]

INTRODUCTION
Integration of potential sex effects into biomedical research is now a requirement. The U.S. National Institutes of Health (NIH) implemented a policy [NOT-OD-15-102] expecting research design, analysis and reporting to account for the role of sex as a biological variable (SABV) in vertebrate and human studies.

In anticipation of this, emergency medicine (EM) researchers developed consensus on a sex and gender specific agenda that would guide research in emergency care for the next decade. The proceedings demonstrated the expanding influence that sex (sex chromosomes XX or XY) and gender (psycho-social identity) have on disease presentation, performance of diagnostic testing, treatment responses and outcomes.¹ Additionally, provider behavior, healthcare utilization and disparities in delivery of medical care were also demonstrated to have effects linked to patient sex and gender.¹²

As the field of EM continues to align itself with national research priorities, new data continues to surface supporting significant differences of SABV in patient presentation, diagnostic workup, treatment and outcomes. This is a narrative review on the effect of SABV on three commonly seen EM conditions: acute myocardial infarction (AMI), acute ischemic stroke (AIS) and general administration of pharmacologic preparations. These examples are provided to briefly introduce the EM clinician and researcher to a sampling of the available SABV data, as well as to highlight the many gaps in knowledge that will need to be filled by future research endeavors in SABV in emergency care. Additionally, we discuss the cognitive steps required to bridge the gap between discovering the ever-increasing evidence that will result as SABV continues to be incorporated into EM research and the understanding of how to use this data to impact the clinical care of patients.

Due to the evolving terminology that now exists within the continuum of sex and gender, we have provided current definitions as an Appendix. Further discussion of the social construct of gender as well as the health-related issues of transgender patients are beyond the scope of this manuscript.
Sex as a Biological Variable in EM Research and Clinical Practice
McGregor et al.

Cognitive Integration of Sex as A Biological Variable (SABV) by the Practicing Emergency Provider

Emergency physicians (EP) will need to learn how to incorporate evidence where SABV may affect clinical manifestation of disease as well as diagnostic and treatment decisions. Table 1 summarizes the cognitive steps EPs can use to assist the integration of this evidence depending upon the patient’s sex. The most important first step toward integration and clinical care is to accurately identify each patient’s biological sex. This may require clarification by the patient, as it does not always follow stereotypical norms, and the chromosomal sex (XX vs. XY) may be distinct from gender identity.

After performing the appropriate focused physical exam and assessment, it is important to recognize how the patient’s sex may affect the clinical manifestation and presentation of the current illness. Routinely asking yourself, “How would the presentation, diagnostic workup or management of this patient change if they were the opposite sex?” is an important cognitive step in acknowledging this new science and aids in training ourselves to think differently.

When considering diagnostic workup, consider the potential limitations that may exist depending on patient sex. For instance, women are more likely to have non-obstructive cardiovascular disease compared to men. Many of the diagnostic tools used to detect cardiovascular disease in the emergent setting have been based upon detection of macrovascular / obstructive coronary artery disease (CAD). This will leave microvascular / non-obstructive disease or a non-plaque mediated cause of ischemia often undetectable. These limitations should be understood and discussed with the patient.

As research that includes SABV continues, more sex-specific thresholds for biomarkers and laboratory value references will become increasingly available. For instance, sex-specific thresholds now exist for troponin. Sex-specific laboratory value reference ranges are available for hemoglobin/hematocrit, calcium, creatinine, cholesterol and uric acid. The patient’s biological sex, gender, and gender identity will need to be considered when interpreting these references ranges regarding sex-specific norms. Knowledge and accurate utilization of these ranges will increasingly become important.

Pharmacokinetics and pharmacodynamics are now known to be significantly different between women and men and have been demonstrated for many drugs including zolpidem, propofol, and rocuronium. Additionally, indications for initiating medications can also differ by sex. It is crucial that EPs are aware of these differences and remain open to new data as it is published to minimize risk and optimize benefits in the use of medications in the emergency setting.

To aid the emergency care provider in consuming newly released data, as well as achieving the aims of integration of SABV into clinical practice, an effective literature-search strategy is critical. The Texas Tech University Health Sciences Center Sex and Gender Specific Health PubMed Search Tool may help facilitate SABV-based literature assessment as well as clinical decision-making.

ACUTE MYOCARDIAL INFARCTION

Case: A 40-year-old female with obesity, hypertension and one-pack-a-day smoking history was brought to the emergency department (ED) by ambulance for substernal chest discomfort at rest. Electrocardiogram (ECG) showed normal sinus rhythm with new T-wave inversions in I and AVL. Troponin came back at 0.10 (normal <0.05). Your diagnosis is non-ST elevation myocardial infarction (NSTEMI).

AMI is more common in men at a young age. However, young women with AMI are two times more likely than men to die during the hospitalization. This sex-specific mortality disadvantage persists for women 30 days post discharge, and up to five years after the MI. Some attribute this disparity to higher prevalence of comorbidities in women with AMI while others

Table 1. Cognitive steps to integrate SABV into clinical practice with associated examples from current literature.

<table>
<thead>
<tr>
<th>Cognitive Step</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Identify patient sex</td>
<td>Male or Female</td>
</tr>
<tr>
<td>2. Understand sex differences in clinical manifestation of disease</td>
<td>Females more likely to have coronary microvascular disease than men³</td>
</tr>
<tr>
<td>3. Recognize potential limitations in diagnostic testing</td>
<td>Variable prognosis of exercise treadmill test in man versus woman¹⁰</td>
</tr>
<tr>
<td>4. Use any sex-specific thresholds for biomarkers or laboratory value references</td>
<td>Troponin,¹¹ Hemoglobin/Hematocrit, Calcium, Creatinine, Cholesterol and Uric Acid</td>
</tr>
<tr>
<td>5. When available, dose medications based upon sex-specific evidence</td>
<td>Sex-based dosing of analgesia,¹²-¹⁵ antiemetics,¹⁶ sedation medications,¹⁷-¹⁹ neuromuscular blockade,¹⁷,¹² vasopressors or inotropes,¹²,²⁰ anticoagulants for treatment of myocardial infarction²¹</td>
</tr>
<tr>
<td>6. Use Sex and Gender Specific Health PubMed Search Tool</td>
<td><a href="http://www.sexandgenderhealth.org">www.sexandgenderhealth.org</a></td>
</tr>
</tbody>
</table>
point to less aggressive management of women.\textsuperscript{24,25} However, neither entirely explains the higher mortality seen in women—a cohort typically protected by estrogen. When MI occurs despite this protection, it is due to different disease pathology, anatomical differences or variable mechanisms of atherosclerosis.\textsuperscript{26-28}

Table 2 outlines some of the sex differences in the pathophysiology of ischemic syndromes. One in eight women with AMI have a pathophysiology other than the classic thrombo-embolic mechanism that underlies typical AMI.\textsuperscript{27} Women are also more likely to have single vessel disease (resulting in higher rates of false-negative stress tests).\textsuperscript{29} Even in the presence of an abnormal stress test or positive troponin, women are less likely to have >50% obstruction of the coronary artery, a \textit{sine qua non} of heart disease.\textsuperscript{3,26} Ischemia in absence of CAD is most commonly attributed to coronary microvascular dysfunction (CMD). It refers to a group of mechanisms causing endothelial dysfunction of the small vessels (arterioles and prearterioles) that limit the ability of myocardium to increase blood flow in response to stress (coronary flow reserve) resulting in ischemic chest pain.

CMD is five times more common in women and presents a diagnostic challenge as routine testing for obstructive CAD is not sensitive in diagnosing CMD.\textsuperscript{30-32} The EP often encounters these alternate mechanisms of ischemia while evaluating patients with recurrent chest pain, one of the leading causes of readmissions.\textsuperscript{33} CMD is a known cause of recurrent chest pain and needs to be considered in the workup of patients with chest pain who are ruled out for CAD.\textsuperscript{34-35}

Differences in pathophysiology also influence the presentation and risk stratification of AMI. Women, like men, present most commonly with chest pain when having an AMI.\textsuperscript{36} However, they describe it more as \textit{discomfort} than \textit{pain} and are less likely to describe it as “classic” angina, i.e., as exertional substernal chest pain, which is more reliably predictive of obstructive CAD in men.\textsuperscript{37} What also distinguishes the presentation is the number of associated symptoms: Women tend to describe a \textit{cluster} of symptoms such as shortness of breath, fatigue, and radiation of pain, \textit{in addition} to chest discomfort as opposed to men who focus primarily on chest pain.\textsuperscript{38} The cluster of symptoms could therefore “dilute” the presentation when evaluating women with ischemia compared to men. This was seen in a sex-specific study of AMI from Canada,\textsuperscript{39} and summarized in a recent consensus statement on AMI.\textsuperscript{23} While more commonly seen in women, atypical symptoms such as Shortness of breath, epigastric pain, nausea as the sole presentation of AMI constitute only 10-15\% of all STEMI presentations and less than a third of all AMI presentations.\textsuperscript{39,40} Young women with AMI may also present without any chest pain compared to men, potentially explaining the higher mortality seen in this age group.\textsuperscript{41}

While assessment of cardiac risk factors in the ED has been questioned, data supports their use for cardiovascular risk stratification particularly in young patients.\textsuperscript{42,43} Certain risk factors impart a differential risk by sex. Examples are included in Table 1 but the list of novel risk factors is rapidly evolving. The EP may inquire specifically about these risk factors based on patient sex and incorporate them in assigning the pretest probability for ischemia for that patient. For instance, the presence of diabetes in a young patient with chest pain would warrant some caution as diabetes has been known to equalize the cardiovascular risk protection typically seen in young women compared to similarly aged men.\textsuperscript{34,45}

Several risk stratification tools currently exist to aid the EP in evaluating patients with chest pain. The more commonly used scores include the Thrombolysis in Myocardial Infarction (TIMI) score, the HEART (History, ECG, Age, Risk factors, Troponin) score or the Emergency Department Assessment of Chest Pain Score (EDACS); all aim at identifying low-risk patients who could be safely discharged early from the ED.\textsuperscript{46} While most of these scores considered sex/gender as a control variable in the original derivation cohorts, not many validated their performance independently among men and women. In the few studies that did evaluate these scores by sex, differential performance was seen despite similar discriminatory and calibration characteristics of the scores.\textsuperscript{48} Men were noted to have worse outcomes, suggesting that early discharge for low-risk men by HEART or TIMI scores may be less safe for men as compared to women with acute chest pain. This is likely due to the higher rates of major adverse outcomes (MACE) seen in men as compared to women with AMI, highlighting the need for sex-specific risk stratification scores.\textsuperscript{49} The differential effect of sex was considered in the EDACS in its final model.\textsuperscript{46} It performed well in its original validation cohort with 100% sensitivity and 59\% specificity for low-risk patients. While the EDACS is a step forward by incorporating patient sex in considering cardiac risk, it still needs validation in studies evaluating its performance independently by sex.\textsuperscript{49}

SABV can influence the interpretation of diagnostic tests for AMI.\textsuperscript{11} Troponin testing is the cornerstone of diagnosing AMI in the ED. A European study of 1,126 patients with acute coronary syndrome (55\% men and 45\% women) used a conventional troponin assay to diagnose 19\% men and 11\% women with AMI.\textsuperscript{11} The use of a high-sensitivity troponin assay added 4-5\% AMI cases to each group. Most interestingly, when using a sex-specific threshold for troponin that has a lower cut-off for women (given their lower heart muscle mass), the diagnosis of MI doubled in women and did not vary significantly for men. Patients who were reclassified using the sex-specific cut-off had worse outcomes than patients with conventionally diagnosed MI.\textsuperscript{11} High-sensitivity troponin assays were only recently approved by the FDA for use in the U.S. and therefore need validation in U.S. populations. However, the results are intriguing and may influence the future of cardiac marker analysis.\textsuperscript{49}
Table 2. Sex differences in pathophysiology of cardiac ischemic syndromes.

<table>
<thead>
<tr>
<th>Acute coronary syndromes</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anatomical area of coronary obstruction</td>
<td>Large and small vessels</td>
<td>Large vessels</td>
</tr>
<tr>
<td>Pathophysiology of ischemia</td>
<td>Plaque rupture</td>
<td>Plaque rupture&lt;sup&gt;58&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Plaque erosion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternate mechanisms: &lt;sup&gt;23&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>coronary artery spasm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>spontaneous coronary artery dissection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>embolization,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>coronary microvascular dysfunction</td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Chest pain most common</td>
<td>Chest pain most common</td>
</tr>
<tr>
<td></td>
<td>Often with cluster of associated symptoms&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Fewer associated symptoms</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traditional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>2-fold higher&lt;sup&gt;59&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>2-fold higher&lt;sup&gt;60&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>60% higher&lt;sup&gt;43&lt;/sup&gt;</td>
<td>Higher&lt;sup&gt;23&lt;/sup&gt;</td>
</tr>
<tr>
<td>Physical inactivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel risk factors</td>
<td>60% higher</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>Higher&lt;sup&gt;61&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Lupus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercoagulable states</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy associated</td>
<td>Preeclampsia gestational diabetes, preterm labor and neonatal death double the risk for AMI.&lt;sup&gt;62-65&lt;/sup&gt;</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin</td>
<td>Higher-sensitivity troponin using sex-adjusted cut-offs picked up twice as many with worse outcomes.&lt;sup&gt;31&lt;/sup&gt;</td>
<td>High-sensitivity troponin made no significant change for diagnosing AMI compared to conventional troponin</td>
</tr>
<tr>
<td>Risk scores</td>
<td>Men with low-risk HEART and TIMI score have worse outcomes.&lt;sup&gt;47,48&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Stress imaging</td>
<td>For intermediate-high risk, sensitivity can be increased with stress echo or nuclear stress with imaging.</td>
<td>ETT has higher sensitivity</td>
</tr>
<tr>
<td>Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>PCI preferred over thrombolytic therapy</td>
<td>PCI preferred over thrombolytic therapy</td>
</tr>
<tr>
<td></td>
<td>Door-to-balloon times longer&lt;sup&gt;21&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>NSTEMI</td>
<td>Similar benefit</td>
<td>Similar benefit</td>
</tr>
<tr>
<td></td>
<td>Lower dose of anticoagulants</td>
<td></td>
</tr>
<tr>
<td>Non-CAD ischemia</td>
<td>Conservative management with secondary prevention</td>
<td></td>
</tr>
<tr>
<td>Prognosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>Higher at younger age&lt;sup&gt;32&lt;/sup&gt;</td>
<td>Higher overall</td>
</tr>
<tr>
<td>Readmissions for chest pain</td>
<td>Higher</td>
<td></td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; HEART, HeartScore is a cardiovascular disease risk assessment and management tool developed by the European Society of Cardiology; TIMI, Thrombolytics in Myocardial Infarction, ETT, exercise tolerance test; PCI, percutaneous coronary intervention.
Interpretation of stress tests may also vary depending on whether the patient is a man or a woman. For instance, an exercise tolerance test has 60% sensitivity in women (often with single vessel disease) as opposed to 71% sensitivity in men (often with multi-vessel disease). Women are also less likely to achieve maximal heart rate crucial for correct interpretation and more likely to be converted to pharmacological testing. Sensitivity for a pharmacological nuclear scan in general is less (60%) compared to an exercise perfusion scan (85%). Hence, women are more likely to have tests with lower sensitivity than men. Additional considerations, such as radiation risk in breast tissue with computed tomography (CT) angiography, further influence the optimal choice of test for men vs. women.

With a rapidly growing body of science on ischemic syndromes beyond CAD, an EP will be tasked to incorporate this knowledge into his/her assessment of chest pain patients to capture all cases of cardiac ischemia. Diagnosing non-CAD causes of ischemia can, however, be challenging. In contrast to CAD, CMD can present as angina induced by atypical triggers such as change in temperature or high stress. Also, conventional tests such as troponin or stress test may be normal with CMD. Our preliminary work indicates that up to 40% of ED patients with recurrent chest pain have CMD by advanced imaging. Patients are suspected for CMD based on recurrent symptoms consistent with angina and lack of evidence for obstructive CAD. An EP may refer such patients for additional testing such as cardiac positron emission tomography (PET), magnetic resonance imaging (MRI) or even coronary reactivity testing by coronary angiogram so a definitive diagnosis of ischemia may be made.

Current guidelines for treating MI are similar for men and women including benefits of anticoagulants, with some sex-specific nuances. For NSTEMI due to CAD, early invasive therapy is harmful for low-risk women and beneficial for all-risk men. In addition, anticoagulants have to be weight-adjusted to reduce the risk of bleeding, more often seen in women. For STEMI, newer therapies based on plaque composition such as aspiration thrombectomy and catheter-directed lytic therapy without implantation of stents are on the horizon. A small study of these non-stent therapies indicates that the outcomes may be comparable to conventional therapies. The biggest changes on the horizon are with regard to the treatment guidelines for non-CAD related causes of ischemia. Revascularization is not indicated for some causes of AMI (such as coronary artery dissection) or applicable (coronary artery vasospasm). Additional therapies may need to be adapted to the underlying cause, for instance calcium channel blockers for vasospasm, early use of statins and ACE inhibitors for non-plaque AMI, or no anticoagulants for coronary artery dissection. For treatment of CMD and recurrent angina, at minimum patients require cardioprotective medications such as aspirin, statins and an aggressive symptom-management plan that may include ACE-inhibitors and statins, while nitrates and beta-blockers appear ineffective. Given the effect of SABV in rapidly changing the landscape of ischemic heart disease, this review is meant to serve as a primer for a practicing physician.

**ACUTE ISCHEMIC STROKE**

Case: A 39-year-old female two weeks post-Cesarean section with rheumatic heart disease and paroxysmal atrial fibrillation (anticoagulation held) developed an acute right MCA stroke syndrome (NIH Stroke Scale (NIHSS) score of 19; left
side flaccid and plegic in arm and leg). Intravenous (IV) tissue plasminogen activator (TPA) had no improvement; the patient underwent mechanical thrombectomy 5.5 hours after symptom onset. A week later symptoms had nearly resolved.

Women face a higher lifetime risk of stroke having ~55,000 more strokes than men each year, and have a higher annual stroke death rate (fifth cause of death for men; fourth for women). Overall, when age adjusted the incidence of all cerebrovascular disease is higher in men than women at younger ages but not older ages. From 1980 to 2005 there was a greater age-adjusted decline in stroke death rates in men than in women. There are roughly 6.8 million stroke survivors in the United States living after having had a stroke, including 3.8 million women and 3 million men. Overall, one in five women will have a stroke at some point in their lives. Regarding strokes in young people— in some studies men appear to have a higher rate in the 35- to 44-year-old age group, while other population-based analyses reveal a higher incidence among women under 30 years old.

Sex-specific considerations in AIS are summarized in Table 3. Although the absolute risk of stroke is low, there are several sex-specific risk factors unique to women that increase the relative risk of stroke—hormone therapy (HT), migraine headaches with aura in combination with tobacco use, and preeclampsia/eclampsia. Of note, atrial fibrillation is more common in women contrasted to men over the age of 75 while rates below this age are equivocal. The specific combination of hypertension and HT further increases the risk of stroke, and the post-partum hypercoagulability phase may now extend out to 12 weeks post-delivery. Recently, the American Stroke Association (ASA) published guidelines for prevention of stroke in women. However, there is still opportunity for future progress, including addressing sex and gender differences in other phases of stroke care.

Several key sex differences have been evaluated in secondary analyses of large registries and other investigations. Population-based data on sex differences in the acute phase of presentation indicate conflicting results. Some studies report that women have a higher propensity for presenting with non-traditional stroke symptoms (i.e., altered mental status) contrasted to their male counterparts who have higher odds of presenting with specific symptoms (i.e., focal findings such as paresthesia, ataxia, and diplopia) in combination with non-specific symptoms (i.e., pain, disorientation, generalized weakness, fatigue). Others studies have not observed a consistent sex difference in the prevalence of traditional vs. non-traditional symptoms “making it difficult to craft a public health message about gender differences in early warning signs of stroke.” It is possible that the above investigations may be prone to length bias due to delayed presentations to the ED. One study observed that the risk of delay in hospital arrival was three times greater for women with acute strokes contrasted to men. However, other literature, while not focusing overall on time to presentation, has demonstrated women are more likely to arrive via ambulance compared to men while being less likely to receive TPA. Further investigation in this area is necessary to evaluate these differences.

For stroke etiology, some studies suggest women may be more likely to have large territory strokes contrasted to lacunar/smaller embolic syndromes more prevalent in men. But interpretation is limited as other studies posit that women are more likely to have cardioembolic strokes contrasted to men. Such studies do not specifically differentiate risks in different age categories as the etiology of stroke varies in young to geriatric patients. To further complicate matters for the EP, patients presenting with stroke mimics, such as complex migraine tend to be younger and are more likely to be female. Navigating this paradox—the simultaneous existence of atypical presentations and observed differences in treatment rates—is a difficult task for the EP. One solution is to have a system that can rapidly recruit the aid of a stroke specialist (i.e., via telemedicine) and in some cases perform definitive diagnostic testing (i.e., hyperacute MRI) in cases where diagnostic uncertainty exists. While the current literature does not demonstrate sex differences in the rates of missed strokes, further investigation in this area merits consideration.

A concerning observation as cited above is that women are less likely to receive IV TPA. This could be especially deleterious to outcomes, as other pooled analyses of clinical trials suggest

<table>
<thead>
<tr>
<th>Table 4. Examples of sex-based differences in response to pharmacologic therapies in the emergency department.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacokinetic differences</strong></td>
</tr>
<tr>
<td>Volume of distribution</td>
</tr>
<tr>
<td>Protein binding of drugs</td>
</tr>
<tr>
<td>Metabolism and transport of drugs</td>
</tr>
<tr>
<td><strong>Pharmacodynamic differences</strong></td>
</tr>
<tr>
<td>Number of receptors &amp; receptor binding</td>
</tr>
<tr>
<td>Variability in ion channels</td>
</tr>
</tbody>
</table>

QTc, QT interval corrected for heart rate; CNS, central nervous system.
Given the same dose of a neuromuscular blocking agent like rocuronium or vecuronium, male patients will have a lower and effective clinical practice.

As in the management of this trauma patient, EPs frequently manage patients with pharmacotherapies. Physiological, hormonal, and genetic differences between male and female patients affect both drug response and rate of adverse drug reactions (ADR), with female patients experiencing higher drug concentrations and more ADRs, even after accounting for weight-based dosing. Examples of sex-based differences in response to pharmacologic therapies in the ED are summarized in Table 4. Historically, females have been excluded from pharmaceutical development research and sex-based dosing recommendations are rarely made. Sex alters both pharmacokinetics and pharmacodynamics. Sex differences have been reported in plasma volume, protein concentration, gastric emptying and gut transit times, drug metabolism and clearance, drug transporter function, drug receptor concentration and rates of polypharmacy.

EPs providing opioid pain control should note that morphine causes lower rates of respiratory depression and has more rapid onset and offset in males. Female patients are more sensitive to pain in experimentally-induced pain studies; have increased willingness to report pain in studies of pain tolerance; have higher rates of chronic painful conditions in epidemiological studies studying pain in multiple body sites; and may require higher doses of opioids to obtain pain relief, which may place female patients at increased risk for adverse events, particularly given an increased risk of opioid-induced respiratory depression compared to males. Given the available data, careful dose titration and close monitoring for both effectiveness and opioid-induced side effects is warranted even when using standard weight-based dosing of morphine. In the case above, the provider may note that male patients may be able to tolerate higher doses of morphine, may be less likely to report pain, and are at decreased risk for adverse effects from opioids compared to females.

Underlying QTc prolongation and drug-induced torsades de pointes (Tdp) from many antiemetics, antipsychotics, antiarrhythmics, and antimicrobials commonly administered in the ED is more common in females and may vary within the menstrual cycle. Underlying mechanisms may be related to protective effects of testosterone in males, pro-arrhythmic effects of estrogens in females, and sex-based differences in drug pharmacokinetics and ion channel expression. As an example, if this male trauma patient is treated with the antiemetic ondansetron, baseline QTc prolongation and therefore drug-induced Tdp is less likely than in a female patient. A baseline ECG to assess QTc interval could be performed prior to administering QTc prolonging medications in patients at higher risk for Tdp, such as female patients, patients with congenital long QT, or patients with concomitant use of another QT-prolonging medication.

Given the same dose of a neuromuscular blocking agent like rocuronium or vecuronium, male patients will have a lower...
serum drug concentration, slower onset, and shorter duration of action compared to females. In the case of this male patient, the provider may note that paralytic effect during rapid sequence intubation may be shorter in duration than it would be for a female patient receiving standard doses of rocuronium. Such sex differences have not been found with succinylcholine.

When serial bolus dosing of propofol is used to titrate conscious sedation to effect, male patients require lower and fewer doses of propofol to maintain the same blood concentrations of drug as female patients, and often wake up more slowly than female patients. Percentage body fat is higher in females, which lowers the blood concentration of lipid soluble drugs such as propofol. Should this male patient require deep sedation using propofol, the EP may note that the patient may wake up more slowly, and require lower doses within the standard dosing range for propofol when compared to a female patient.

Male patients metabolize vasopressor and inotropics commonly administered in the ED such as norepinephrine, epinephrine, and dopamine at higher rates than female patients due to 25% higher catabolic enzyme activity. If the resuscitation of this male trauma patient warrants the titration of a vasopressor or inotrope to effect, the clinician may find that this male patient requires doses on the higher end of the normal dosing range for a vasopressor or inotrope.

Given that many of the medications provided in the ED are already dosed in ranges and titrated to effect, providers should be aware that female patients may be more susceptible to side effects from standard dosing of morphine; more sensitive to standard doses of inotropes, vasopressors, and non-depolarizing paralytics such as rocuronium; and less sensitive to standard doses of propofol than male patients. An awareness of these differences that have been reported in the literature can help clinicians be cognizant of sex-based differences that may occur in response to medication administration within dosing ranges commonly used within the standard practice of EM. Finally, given these sex-based differences in drug response and adverse outcomes, SABV should be considered in all phases of the development of new drugs designed to be used in the ED.

**LIMITATIONS**

Despite the importance of both variables, sex and gender, in research and the important considerations they impart in the clinical care of women and men, this brief narrative review focused on SABV in research as it relates to ED clinical care. The ability to accurately measure and access the impact of gender identity on the delivery of medical care is complex and currently without well agreed-upon validated measurement tools. Despite this, the authors feel it is important to initially assess each patient’s biological sex and current gender identity, as it will begin the process of realizing the fact that these two variables may not always be congruent.

The authors also discovered a paucity of SABV being included within EM clinical practice guidelines and available research, highlighting this as an area for future research and inclusion.

**CONCLUSION**

With the new NIH requirement to integrate SABV into research design, analysis and reporting, the evidence for the role of patient sex in medical care is growing. As these three clinical scenarios demonstrate, evidence for incorporating SABV in clinical care has immediate implications for the ED patient. The cognitive steps outlined in the manuscript are designed to prepare EM clinicians to identify their patients based upon biological sex, and to become more cognizant of sex-based variability in presentation of disease, appropriateness of diagnostic testing and interpretation of results. Additionally, better incorporation of SABV will allow for safe and effective sex-based treatment in EM. An awareness of known SABV factors in the field of EM will prepare the clinician to consume emerging data in this area. We encourage the utilization of the validated PubMed search tool described to assist the emergency physician in extracting new evidence through the lens of this important biological variable.

Translation of new knowledge of SABV to the bedside requires an awareness of both the available literature and the knowledge gaps that exist in understanding of how sex-based research will ultimately impact patient care. This manuscript details three specific clinical scenarios in which sex based care is imperative, however, much information is still needed to better dissect the role of SABV in all aspects of emergency care. It is incumbent on the astute emergency care provider to consciously embrace emerging evidence in order to provide the best clinical care to their patients. Sex is not simply a descriptor, but a biologic variable that has consequences on risk stratification, utilization of diagnostic tests, and appropriateness of pharmacologics ordered.

**Address for Correspondence:** Alyson J. McGregor, MD, MA, Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Division of Sex and Gender in Emergency, 593 Eddy St., Claverick 100, Providence, RI 02903. Email: amcgregormd@gmail.com.

**Conflicts of Interest:** By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.

**Copyright:** © 2017 McGregor et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: [http://creativecommons.org/licenses/by/4.0/]
Sex as a Biological Variable in EM Research and Clinical Practice

REFERENCES


62. Wenger NK, Ouyang P, Miller VM, et al. Strategies and Methods for Clinical Scientists to Study Sex-Specific Cardiovascular Health and...
97. Office U. S. G. A. Drug Safety: Most Drugs Withdrawn in Recent
Sex as a Biological Variable in EM Research and Clinical Practice

McGregor et al.


